>Immune Checkpoint Proteins
>Biotinylated Human B7-2 / CD86 / CD28 Ligand 2 Protein, Fc Tag, Avi Tag
This protein carries a human IgG1 Fc tag at the C-terminus, followed by a Avi tag (Avitag™).
The protein has a calculated MW of 53.8 kDa. As a result of glycosylation, the protein migrates as 66-100 kDa under reducing (R) condition, and 120-140 kDa under non-reducing (NR) condition (SDS-PAGE).
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, pH7.5. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
No activity loss was observed after storage at:
Biotinylated Human B7-2, Fc Tag on SDS-PAGE under reducing (R) and no-reducing (NR) conditions. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Flow Cytometry assay shows that recombinant Biotinylated Human B7-2, Fc Tag, Avi Tag (Cat. No. CD6-H82F5) can bind to CD28 expressed on Jurkat E6.1 cells. The concentration of B7-2 used is 1.5 μg/ml (Routinely tested).
FACS analysis shows that the binding of Biotinylated Human B7-2, Fc Tag to CD28 expressed on Jurkat E6.1 was inhibited by increasing concentration of neutralizing anti-CD28 antibody. The concentration of B7-2 used is 1.5 μg/ml. The IC50 is 0.031 μg/ml (Routinely tested).
Flow Cytometry assay shows that Biotinylated Human B7-2, Fc Tag (Cat. No. CD6-H82F5) can bind to 293 cell overexpressing human CTLA-4. The concentration of Human B7-2 is 2 μg/ml (Routinely tested).
FACS analysis shows that the binding of Biotinylated Human B7-2, Fc Tag (Cat. No. CD6-H82F5) to 293 overexpressing CTLA-4 was inhibited by increasing concentration of neutralizing anti-human CTLA-4 antibody. The concentration of Human B7-2 is 2 μg /ml. The IC50 is 1.014 μg/ml (Routinely tested).
The Biotin AviTag technology is covered by U.S. Pat. No: 5,874,239 and includes any and all materials, methods, kits and related derivatives claimed by this patent. The purchase of the Acrobiosystems’s Avitag™ proteins confers to the purchaser the limited right to use the Avitag™ technology for non-commercial, or research use, or for purposes of evaluating the Avitag™ technology.
Commercial use of the Avitag™ technology to manufacture a commercial product, or use of the Avitag™ technology to facilitate or advance research which will be applied to the development of a commercial product requires a license from Avidity, LLC. Examples of Commercial use include, but are not limited to biosensors, diagnostics, therapeutic applications, proximity assays, and drug screening assays.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
Price(USD) : $350.00
Price(USD) : $1380.00
This web search service is supported by Google Inc.